Senores Pharmaceuticals Expands US Portfolio with Acquisition of Two USFDA-Approved ANDAs from Teva USA

Senores Pharmaceuticals Ltd. has announced a strategic acquisition that strengthens its presence in the U.S. generics market. Through its wholly owned subsidiary Senores Pharmaceuticals Inc., USA, the company has acquired two Abbreviated New Drug Applications (ANDAs) approved by the U.S. Food and Drug Administration (USFDA) from Teva USA. This move marks another milestone in Senores’ aggressive expansion strategy and underscores its commitment to building a robust pipeline of high-value generic drugs.

Key highlights from the acquisition:  
- Senores acquired USFDA-approved ANDAs for Roflumilast 250 mcg and 500 mcg tablets  
- The products were purchased from Breckenridge Pharmaceutical Inc., a U.S. subsidiary of Towa International  
- Roflumilast is used in the treatment of chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis  
- The U.S. market size for Roflumilast is approximately USD 32 million as of June 2024, according to IQVIA  
- The acquisition was funded through proceeds from Senores’ Initial Public Offering (IPO)

Strategic rationale and therapeutic focus:  
Senores’ acquisition aligns with its strategy to enter niche therapeutic areas with high unmet needs.  
- Roflumilast is a selective phosphodiesterase-4 inhibitor, offering targeted treatment for COPD patients with a history of exacerbations  
- The product complements Senores’ existing respiratory and chronic care portfolio  
- The company aims to leverage its manufacturing and distribution capabilities to scale access across the U.S. and other regulated markets  
- This acquisition also helps Senores establish a foothold in the chronic bronchitis therapy segment

Operational and manufacturing capabilities:  
Senores’ infrastructure is well-equipped to support the commercialization of the newly acquired products.  
- The company operates two formulation manufacturing facilities: one in Atlanta, USA (USFDA-approved), and another in Chhatral, Ahmedabad (WHO-GMP certified)  
- It also owns two API manufacturing units in Chhatral and Naroda, Gujarat  
- Senores has over 260 product registrations and 530 product applications across more than 40 countries  
- The company’s R&D centers in the U.S. and India focus on complex generics and differentiated dosage forms

IPO utilization and growth strategy:  
The acquisition is part of Senores’ broader plan to deploy IPO proceeds toward strategic product expansion.  
- The company raised capital to fund acquisitions, scale manufacturing, and enhance R&D capabilities  
- Recent acquisitions include 14 ANDAs from Dr. Reddy’s Laboratories, expanding Senores’ U.S. portfolio significantly  
- The company’s current U.S. portfolio includes 27 ANDAs and 21 CMO/CDMO commercial products  
- Senores is targeting both regulated and semi-regulated markets with a focus on high-growth therapeutic segments

Market impact and future outlook:  
Senores’ latest acquisition is expected to drive revenue growth and improve its competitive positioning.  
- The U.S. generics market continues to offer attractive opportunities for cost-effective alternatives to branded drugs  
- Senores plans to launch the acquired Roflumilast tablets in Q3 FY26, pending final distribution approvals  
- The company is also exploring partnerships with specialty clinics and government procurement channels  
- Continued focus on respiratory, oncology, and chronic care segments will guide future acquisitions

Senores Pharmaceuticals’ acquisition of two USFDA-approved ANDAs from Teva USA marks a strategic leap in its U.S. expansion journey. With strong manufacturing capabilities, a growing product pipeline, and a clear focus on niche therapies, the company is poised to become a formidable player in the global generics landscape.

Sources: Senores Pharmaceuticals Media Release, Express Pharma, Medgate Today